The Pipeline Café features academic innovators who are hand selected to present their discoveries, which are available for partnering, in two poster sessions. The academic innovators will be available for discussions at their posters as well as one-on-one partnering meetings.
2018 Pipeline Cafe Participants:
V-3612 – Bone anabolic product candidate for osteoporosis
Suresh Anaganti PhD, CEO, AJES LifeSciences LLC
A platform for developing drug and cell-based therapeutics targeting fat metabolism for treatment of obesity and metabolic disease
Luis C. Santos, PhD, Ardent Cell Technologies
Application of Inkjet-printed Graphene Sensors for the Detection and Prevention of Foot Ulcers in Diabetic Patients
Linh Le, CEO & Founder and Olivia Schreiber, Community Engagement Manager, Bonbouton
MtLDL detection to diagnose childhood tuberculosis
Xinxin Yang, Ph.D. Senior Scientist & Nicole S. Sampson, PhD President and Co-Founder, Chronus Pharmaceuticals, Inc.
Evaluation of a Novel Infection PET Diagnostic
Fereidoon Daryaee, Ph.D. Senior Scientist * Peter J. Tonge, Ph.D. Co-Founder, Chronus Pharmaceuticals, Inc
SmartBio – Next Generation Freezing and Thawing Devices for Enhanced Biologic Cryopreservation
John M. Baust, PhD, President and Lead Scientist, CPSI Biotech
A rapid and highly-efficient platform for the development of human monoclonal antibodies to treat infectious diseases
Raymond A. Alvarez, PhD, Co-founder & CEO, Ichor Biologics
Optical imaging of liver fat accumulation for drug discovery and diagnostics
Prakrit V. Jena, PhD, Co-Founder and CEO, LipidSense
Implantable Nanosensor for Early-Stage Ovarian Cancer Detection
Daniel A. Heller, PhD, Head, Cancer Nanomedicine Laboratory, Memorial Sloan Kettering Cancer Center
Feasibility of a Digital Health Technology to Engage Heart Failure (HF) Outpatients and Their Providers to Prevent Avoidable Readmissions
Laurie Thackeray, CEO, RecoverLINK
Development of a kinetics-driven PK/PD model to predict the efficacy of Btk inhibitors in patients with CLL/DLBCL
Peter J. Tonge, Ph.D. Director, Center for Advanced Study of Drug Action; Professor of Chemistry and Radiology, Stony Brook University
rhMFG-E8 for Acute Kidney Injury (AKI)
Max Brenner, MD, PhD, Director of Drug Discovery, TheraSource LLC